How Bio­con Bi­o­log­ics is tak­ing on the US biosim­i­lars mar­ket

Bio­con Bi­o­log­ics is bet­ting big that it can be a top US biosim­i­lars com­pa­ny.

With its $3 bil­lion ac­qui­si­tion of Vi­a­tris’ biosim­i­lar port­fo­lio last No­vem­ber …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER